Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry.
Revolution Medicines reported on 13 April what many are calling a transformative moment for oncology, with Phase 3 RASolute 302 results showing its oral drug daraxonrasib nearly doubled overall survival in previously treated metastatic pancreatic ductal adenocarcinoma. Patients taking daraxonrasib lived a median of 13.2 months compared to 6.7 months for standard chemotherapy, a hazard ratio of 0.40 representing a 60% reduction in the risk of death. The company intends to seek FDA approval using a Commissioner’s National Priority Voucher for a quicker review, and the data will be presented at the 2026 ASCO Annual Meeting.
The UK government announced on 14 April more than £80 million of new investment in UK life sciences, unlocked through its Life Sciences Innovative Manufacturing Fund. The package includes a £45 million commitment from Accord Healthcare to boost production of oncology and chemotherapy medicines at its Barnstaple site, and £10 million for the University of Birmingham’s Precision Health Technologies Accelerator to build three new GMP-standard cleanrooms for near-patient biomanufacturing of cell and gene therapies and mRNA vaccines. The investments are expected to create over 500 new jobs and bring total UK life sciences investment this year to £600 million.
The UK formally signed off on the US-UK pharmaceutical trade deal in early April, making Britain the only country in the world with zero tariffs on pharmaceutical exports to the US for at least three years. As part of the arrangement, NICE raised its cost-effectiveness threshold by 25% from April 2026, moving from £20,000 to £30,000 per QALY to £25,000 to £35,000, the first such increase in over 25 years. The NHS rebate rate on branded medicines has also been reduced from 22.9% to 15%, aimed at making the UK a more attractive market for pharmaceutical investment and new drug launches.
Kailera Therapeutics set a new record for US biotech IPOs on 17 April, raising $625 million in an upsized offering at $16 per share. Shares surged 63% on debut to close at $26, giving the obesity-focused company a market value of approximately $3.1 billion. Kailera is advancing its lead injectable GLP-1/GIP dual agonist ribupatide through three global Phase 3 trials.
Johnson and Johnson reported Q1 2026 results on 14 April, posting reported sales of $24.1 billion, up 9.9% year-on-year, beating analyst expectations of $23.6 billion. The company raised its full-year 2026 guidance to estimated reported sales of $100.8 billion, becoming the first major pharma company to report this earnings season.
In further life science news 20 April 2026, the FDA on 13 April granted full approval to Travere Therapeutics‘ Filspari (sparsentan) for focal segmental glomerulosclerosis, making it the first and only approved medicine for FSGS in adults and children aged 8 years and older. The drug already holds approval for IgA nephropathy, and the expanded indication opens up a total addressable population of over 100,000 patients in the US.
Eli Lilly agreed on 14 April to acquire Houston-based CrossBridge Bio for up to $300 million, adding a dual-payload antibody-drug conjugate platform to its growing oncology pipeline. CrossBridge’s lead candidate CBB-120, a TROP2-targeting ADC, is expected to enter clinical trials later this year. The deal follows Gilead’s $5 billion acquisition of ADC specialist Tubulis the previous week, underscoring the intensifying race for next-generation cancer medicine technologies.
AbbVie entered a global licensing deal with China-based Haisco Pharmaceutical on 13 April worth up to $745 million, marking AbbVie’s first foray into pain medicines. The deal gives AbbVie rights to a portfolio of pain candidates currently in preclinical through Phase 1 development, where rival Vertex Pharmaceuticals currently leads thanks to its approved NaV1.8 inhibitor Journavx.
Replimune was dealt a second FDA rejection for its melanoma therapy RP1 on 10 April, receiving a complete response letter for its BLA for vusolimogene oderparepvec in combination with nivolumab. The company said the development of RP1 will not be viable without timely accelerated approval and announced 63 job cuts alongside a substantial scaling back of its US manufacturing operations.
Q1 2026 commitments in obesity and diabetes-focused deals reached $22 billion, already surpassing the full-year 2025 total of $20.3 billion, according to a new J.P. Morgan report, reflecting the extraordinary pace of dealmaking in the metabolic disease space so far this year.
That’s your life science news digest for 20 April 2026 – back next Monday with the latest from pharma, biotech and healthcare.
This weekly digest is produced by the Life Science Daily News editorial team. All stories are selected and written independently.
